Synapse - Works

Results (4640)

Costs and trends in pancreatic cancer treatment: A population-based analysis

Meeting Abstract

O'Neill, C. B.; Atoria, C. L.; O'Reilly, E. M.; LaFemina, J.; Elkin, E. B.
Journal of Clinical Oncology (2011)

Phase II single-arm, single-institution trial of neoadjuvant gemcitabine and oxaliplatin treatment (NT) in patients (pts) with resectable pancreas adenocarcinoma (PC)

Meeting Abstract

O'Reilly, E. M.; Jarnagin, W. R.; Brennan, M. F.; Winston, C.; Tang, L. H.; Capanu, M.; Schattner, M.; Chen, L. Y.; DeMatteo, R. P.; DiMaio, C. J.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Is PET scan conversion from positive to negative a prognostic indicator for patients receiving therapy for unresectable liver metastases from colorectal carcinoma (CRC)?

Meeting Abstract

Maddox, G. J.; Chou, J. F.; Capanu, M.; Patel, D.; D'Angelica, M. I.; Kemeny, N. E.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Does the underlying etiology of HCC effect outcome? A single-institution analysis

Meeting Abstract

Ma, J.; Capanu, M.; O'Reilly, E. M.; Kemeny, N. E.; Ang, C.; Gansukh, B.; Kelsen, D. P.; Saltz, L.; Abou-Alfa, G. K.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Clinical outcomes in patients age 40 or younger at diagnosis of synchronous metastatic colorectal cancer: A 20-year experience at Memorial Sloan-Kettering Cancer Center

Meeting Abstract

Lowery, M. A.; Gallagher, D. J.; Capanu, M.; Chou, J. F.; Kemeny, N. E.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results?

Meeting Abstract

Kemeny, N. E.; Schwartz, L. H.; Gonen, M.; Yopp, A. C.; D'Angelica, M. I.; Fong, Y.; Haviland, D.; Gewirtz, A. N.; Allen, P. J.; Jarnagin, W. R.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib

Meeting Abstract

Janjigian, Y. Y.; Groen, H. J.; Horn, L.; Smit, E. F.; Fu, Y.; Wang, F.; Shahidi, M.; Denis, L. J.; Pao, W.; Miller, V. A.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma

Meeting Abstract

Ilson, D.; Janjigian, Y. Y.; Shah, M. A.; Kelsen, D. P.; Tang, L. H.; Campbell, J.; Fuqua, L.; Capanu, M.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Hepatic arterial infusion (HAI) in the treatment of breast cancer with liver metastases (BCLM) in patients (pts) who progressed after hormonal and systemic chemotherapy (CTx)

Meeting Abstract

Herran, L. A.; Jhaveri, K. L.; Seidman, A. D.; Patel, D.; Gewirtz, A. N.; Kemeny, N. E.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors

Meeting Abstract

Han, H. S.; Swanton, C.; Janjigian, Y. Y.; Sutherland, S. C.; Chandarlapaty, S.; Lehman, R.; Hamilton, N.; Knowles, J.; Lee, R.; Yan, L.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save